EXHIBIT 99.1 - RISK FACTORS

                           Forward-Looking Statements

     From  time  to  time,  the  Company  may  make or  publish  forward-looking
statements  relating  to such  matters  as  anticipated  financial  performance,
business  prospects,  technological  developments,  new  products,  and  similar
matters. Such statements are necessarily estimates reflecting the Company's best
judgment based on current information.  The Private Securities Litigation Reform
Act of  1995  provides  a  safe  harbor  for  forward-looking  statements.  Such
statements  are  usually  identified  by the  use of  words  or  phases  such as
"believes,"  "anticipates,"  "expects,"  "estimates,"  "planned," "outlook," and
"goal." Because forward-looking statements involve risks and uncertainties,  the
Company's  actual results could differ  materially.  In order to comply with the
terms of the safe  harbor,  the  Company  notes that a variety of factors  could
cause the Company's actual results and experience to differ  materially from the
anticipated   results  or  other   expectations   expressed  in  the   Company's
forward-looking statements.

     While  it is  impossible  to  identify  all such  factors,  the  risks  and
uncertainties  that may affect the  operations,  performance  and results of the
Company's business include the following:

     1.   The   Company's   revenues  are  highly   dependent  on  research  and
          development  expenditures and compliance  testing  expenditures by the
          pharmaceutical  and  biotechnology   industries.   Decreases  in  such
          expenditures,  including  those  resulting  from  a  general  economic
          decline in these  industries,  could have a material adverse effect on
          the Company.

     2.   The Company's new product, Culex(R) Automated Blood Sampling Device is
          a significant new product.  Non- acceptance or major difficulties with
          the  device  could  have a material  adverse  effect on the  Company's
          business, operations and financial condition.

     3.   The Company has  benefited  from the growing  tendency of companies to
          engage  independent  organizations to conduct  development and testing
          projects. Any reduction in the outsourcing of research, development or
          testing activities,  or any reduction in public funding of science and
          technology  could  have a  material  adverse  effect on the  Company's
          business, operations and financial condition.

     4.   During  2001,  two  major   pharmaceutical   companies  accounted  for
          approximately  30% of the Company's  total  revenues.  There can be no
          assurance  that  the  Company's  business  will  not  continue  to  be
          dependent  on  continued   relationships   with  certain   clients  or
          distributors  or  that  annual  results  will  not be  dependent  upon
          performance  of a few large  projects.  In  addition,  there can be no
          assurance that  significant  clients or distributors in any one period
          will  continue  to be  significant  clients or  distributors  in other
          periods.

     5.   The Company's business is labor intensive and involves the delivery of
          highly specialized  professional services. The Company's future growth
          and  success  depends  in large  part  upon its  ability  to  attract,
          develop, manage and retain highly skilled professional, scientific and
          technical  operating staff. There is significant  competition from the
          Company's   competitors   as  well  as  from  the  in-house   research
          departments of pharmaceutical  and  biotechnology  companies and other
          enterprises  for  employees  with the skills  required  to perform the
          services   offered  by  the   Company.   Although   the   Company  has
          confidentiality agreements with its scientific and technical operating
          personnel, the Company does not have in place covenants not to compete
          that would  directly  preclude the employees  from being employed by a
          competitor. There can be no assurance that the Company will be able to
          attract,  develop,  manage  and retain a  sufficient  number of highly
          skilled  employees  in the  future  or  that it  will  continue  to be
          successful in training,  retaining and managing its current employees.
          The  loss  of a  significant  number  of  employees  or the  Company's
          inability to hire sufficient numbers of qualified employees could have
          a material  adverse effect on the Company's  business,  operations and
          financial condition.

     6.   The  Company  relies  to a  significant  extent  on a  number  of  key
          executives,  including  Peter T. Kissinger,  Ph.D.,  its President and
          Chairman of the Board. The Company maintains key man life insurance on
          Dr. Kissinger in the amount of $1.0 million.  The loss of the services
          of any of the Company's key executives  could have a material  adverse
          effect on the Company's business, operations and financial condition.
<PAGE>

     7.   The Company's business depends in part on government regulation of the
          drug development process by the United States and foreign governments.
          More stringent governmental regulation of the drug development process
          increases  the need for services and products  provided or produced by
          the  Company.  Recently,  legislation  has been  proposed  that  would
          substantially  modify the current  requirements for FDA administration
          of  the  drug  and  device  approval   process.   Under  the  proposed
          legislation,  applications  for approval of new drugs could be made to
          private  accredited  facilities  in lieu of the FDA. As a result,  the
          number of  clinical  trials of new drugs  would be  reduced  and other
          rules  administered by the FDA would be simplified.  Any change in the
          scope of regulatory  requirements  or the  introduction  of simplified
          drug  or  device  approval   procedures  could  adversely  affect  the
          Company's business, operations and financial condition.

     8.   The  Company's  revenues  are  dependent,   in  part,  upon  continued
          compliance with governmental requirements applicable to facilities and
          techniques  used in the  manufacture  of products for clinical use and
          the  provision of services.  The Company's  facilities  are subject to
          scheduled  periodic  regulatory  inspections to ensure compliance with
          FDA  requirements.  Failure on the part of the  Company to comply with
          applicable  requirements  could result in the  termination  of ongoing
          research,  the  discontinuance  of selected  Company  operations,  the
          disqualification of data for submission to regulatory  authorities and
          fines and penalties being assessed  against the Company,  any of which
          could  have a  material  adverse  effect  on the  Company's  business,
          operations and financial condition.

     9.   With respect to its  products,  the Company  primarily  competes  with
          several  large  equipment  manufacturers  and,  with  respect  to  its
          services,  the Company  primarily  competes against in-house  research
          departments of pharmaceutical  and  biotechnology  companies and other
          full-service   CROs.  Many  of  the  Company's   competitors   possess
          substantially greater capital,  technical and other resources than the
          Company.  The Company's  failure to compete  effectively in any one or
          more of these  areas  could  have a  material  adverse  effect  on the
          Company's business, operations and financial condition.

     10.  Generally,  the  Company's  service  contracts  are  terminable by the
          client  upon notice at any time.  Contracts  may be  terminated  for a
          variety  of  reasons,  including  the  client's  decision  to forego a
          particular study,  failure of products to satisfy safety  requirements
          and  unexpected  or undesired  product  testing  results.  The loss of
          business  from a  significant  client or the  cancellation  of a major
          contract or series of commitments could have a material adverse effect
          on the Company's business, operations and financial condition.

     11.  The Company's business is dependent, in part, on its ability to obtain
          patents  in  various   jurisdictions   on  its   current   and  future
          technologies and products, to defend its patents and protect its trade
          secrets and to operate without infringing on the proprietary rights of
          others.  There can be no assurance that the Company's patents will not
          be challenged by third parties or that, if  challenged,  those patents
          will be held valid.  In addition,  there can be no assurance  that any
          technologies  or  products  developed  by  the  Company  will  not  be
          challenged by third parties  owning patent rights and, if  challenged,
          will be held to not infringe those patent rights. The expense involved
          in any patent  litigation can be significant.  The Company also relies
          on unpatented,  proprietary technology,  and there can be no assurance
          that others will not independently  develop or obtain similar products
          or technologies.

     12.  The Company's  business may become subject to other risk factors which
          may be  identified  from time to time in the  Company's  periodic  SEC
          filings and other public announcements.

     Should one or more of these risks or uncertainties  materialize,  or should
underlying assumptions prove incorrect,  actual results may vary materially from
those described in the forward-looking statement. The Company does not intend to
update forward-looking statements.


                                     - 2 -